GoodRx Holdings (GDRX) Earnings Date & Reports

Key Takeaways

• GoodRx Holdings (GDRX) is expected to report its third-quarter 2026 results after the market close on Tuesday, November 3, 2026, with a conference call scheduled for the following morning.
• Wall Street consensus points to earnings of roughly $0.08 per share and revenue of about $202 million for the quarter, compared with $0.08 per share and $196.0 million in the year-ago period.
• Investors will focus on the momentum of Pharma Direct and subscription offerings, which have offset persistent declines in the legacy prescription-transactions business.
• The company recently disclosed that it will restate its 2026 financials after an understatement of Pharma Direct revenue, a development that adds a layer of uncertainty to the quarter.
• Monthly Active Consumers (MACs), a key engagement metric, fell 12% year over year to 5.0 million in the second quarter, reflecting a deliberate shift in strategy.
• For additional context, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages, and browse Trending AI Robots for additional market signals.

Earnings Context and Why It Matters

GoodRx is navigating a strategic pivot away from its traditional prescription-discount transaction model and toward higher-margin, more durable revenue streams, namely Pharma Direct and subscription plans. The third-quarter 2026 report is a critical checkpoint in that transition. In the second quarter, Pharma Direct revenue surged 76% year over year while subscription revenue rose 39%, even as prescription-transactions revenue declined 26%. Management has raised full-year guidance, signaling confidence that the newer businesses will more than offset a shrinking core. For investors, this report will show whether that rebalancing is progressing fast enough to return the company to overall revenue growth.

Earnings Expectations

Analysts expect GoodRx to post roughly $0.08 in earnings per share on approximately $202 million in revenue for the third quarter of 2026, which would mark modest revenue growth from the $196.0 million recorded a year earlier. The bar is set against a backdrop of mixed recent performance: the company has beaten consensus earnings-per-share estimates in only a handful of its recent quarters. Beyond the headline figures, investors will scrutinize Pharma Direct growth, subscription-plan additions, and the trajectory of Monthly Active Consumers. Management's full-year 2026 guidance calls for revenue of $790 million to $805 million and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $240 million to $250 million, so any commentary on reaffirming or adjusting that range will be closely watched.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical companion for investors tracking earnings events like GoodRx's quarterly report.

Market Reaction and Investor Sentiment

Sentiment heading into this report is cautious but attentive. GoodRx shares have been under pressure amid declining consumer engagement and a strategic shift that is still unfolding. A newly disclosed restatement of 2026 financials, tied to an understatement of Pharma Direct revenue under accounting rules, could weigh on investor confidence even if it reflects higher revenue than initially reported. Key risk factors include continued erosion of Monthly Active Consumers, pressure on prescription-transactions revenue, and execution risk as the company scales its subscription and Pharma Direct businesses. A print that shows stronger-than-expected growth in those newer segments could reassure the market, while any softness in engagement metrics may amplify concerns about the pace of the transition.

Forward Outlook and Key Factors to Monitor

Looking past the third-quarter report, investors should monitor whether Pharma Direct can sustain its rapid growth rate. This business has become GoodRx's primary growth engine, and management has signaled expectations for strong full-year expansion. Commentary on GLP-1 access programs and consumer-direct pricing relationships with pharmaceutical manufacturers will offer clues about the durability of that momentum.

Subscription momentum is another focal point. The company has been rolling out condition-specific plans and new offerings such as GoodRx Companion, and subscription-plan growth of 14% year over year in the second quarter suggests early traction. Whether that growth accelerates while the legacy prescription-transactions business stabilizes will shape the path back to overall revenue growth.

Finally, the restatement process and any disclosure around internal-control weaknesses deserve attention. The company expects to report material weaknesses in internal control over financial reporting and is working to file amended quarterly reports. Progress on resolving these matters, combined with any updates to full-year guidance, will be key factors in how investors assess the company's execution and financial reporting quality in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations